Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 35

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 35
---
 registering the issuance of common shares underlying the January 2024 PIPE Warrants under the Securities Act. If such a registration
statement is not effective or available the holder may, in its sole discretion, elect to exercise the January 2024 PIPE Warrants through
a cashless exercise, in which case the holder would receive upon such exercise the net number of common shares determined according to
the formula set forth in the January 2024 PIPE Warrants. No fractional shares will be issued in connection with the exercise of a January
2024 PIPE Warrants. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied
by the exercise price.

Exercise Limitation. A holder will not
have the right to exercise any portion of the January 2024 PIPE Warrants if the holder (together with its affiliates) would beneficially
own in excess of 4.99% of the number of common shares outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the January 2024 PIPE Warrants. However, any holder may increase or decrease
such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective
until 61 days following notice from the holder to us.

Exercise Price. The exercise price per
whole common share purchasable upon exercise of the January 2024 PIPE Warrants is $1.60 per share. The exercise price is subject
to appropriate adjustment in the event of certain share dividends and distributions, share splits, share combinations, reclassifications
or similar events affecting our common shares and also upon any distributions of assets, including cash, stock or other property to our
shareholders.

Subject to certain exemptions outlined in the
January 2024 PIPE Warrants, for the life of the warrant, if we shall sell, enter into an agreement to sell, or grant any option to purchase,
or sell, enter into an agreement to sell, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale,
grant or any option to purchase or other disposition) any common shares or convertible security, at an effective price per share less
than the exercise price of the January 2024 PIPE Warrants then in effect, or a Dilutive Issuance, the number of common shares issuable
upon exercise of the January 2024 PIPE Warrant shall be proportionally adjusted so